Invida Charts 25% Growth Plan, Banking On Selective Partnerships For High-value Products
This article was originally published in PharmAsia News
Executive Summary
SINGAPORE - Big Pharma's slow shift from primary care products to specialty care products like the oncology segment has helped Invida develop robust commercial relationships with multiple partners
You may also be interested in...
Asia Beckons: Italy’s Menarini Wins Invida To Maximize Local Identity
Menarini is attracted to Invida for its speedy growth at the back of its Asia presence. Asia-Pacific region represents 10% of the world’s pharmaceutical market with a projected near-term 20% annual growth rate.
China's Outsource Sales Model Takes A Big Step: SciClone Takes Out NovaMed
SciClone Pharmaceuticals will significantly broaden its commercial footprint across China by acquiring privately owned, Shanghai-based specialty pharma NovaMed Pharmaceuticals for close to $62 million plus potential earnouts in a deal that closed April 18